Other languages Nexalin Technology, Inc.

Equities

NXL

US65345B2016

Delayed Nasdaq Other stock markets 12:58:58 2024-05-22 pm EDT			5-day change	1st Jan Change
1.13 ^USD	-1.76%		-16.92%	+179.13%

May. 10	Nexalin Technology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 25	Nexalin Technology Regains Compliance With Nasdaq Listing Requirement	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nexalin Technology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 10
Nexalin Technology Regains Compliance With Nasdaq Listing Requirement	Apr. 25
Nexalin Technology Accelerates Manufacturing of Its HALO? Clarity Following Successful Usability, Feasibility, and Electrical Testing	Apr. 09
Nexalin Technology, Inc. Announces the Appointment of William A. Hudson, Jr. to Military & Government Advisory Board	Apr. 02
Top Midday Gainers	Mar. 28
Nexalin Technology, Inc. Announces Positive Results of Clinical Study Validating its Gen-2 TACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego	Mar. 28
Nexalin Technology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27
Nexalin Technology, Inc. Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman	Mar. 14
Nexalin Technology, Inc. Announces Positive Results from Clinical Study of Its Gen-2 Tacs Device for Treating Adult Patients with Chronic Insomnia	Mar. 06
Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device	Feb. 08
Nexalin Technology, Inc. Unveils Gen-3 HALO?? Clarity 15 Milliamp Neurostimulation Device	Jan. 11
Nexalin Technology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Nexalin Technology, Inc. Announces Publication of Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal	23-10-16
Nexalin Technology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of Its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms	23-08-07
Nexalin Technology, Inc. and Wider Come Limited Announce Joint Venture Agreement to Advance Commercialization of Nexalin's TACS Devices in the Asia Pacific Region	23-06-01
Nexalin Technology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10
Nexalin Technology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-27
Nexalin Technology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-27
Nexalin Technology, Inc. Appoints Michael Nketiah as Senior Vice President of Quality, Clinical and Regulatory	23-01-24

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Nexalin Technology, Inc.

Equities

NXL

US65345B2016

Other languages

Filters